

Exhibit 5



US007622443B2

(12) **United States Patent**
Anderson et al.

(10) **Patent No.:** **US 7,622,443 B2**
(45) **Date of Patent:** ***Nov. 24, 2009**

(54) **METHOD FOR INHIBITING
PRO-ANGIOGENIC ACTIVITIES OF
ENDOTHELIAL CELLS SELECTIVELY AT A
SITE OF NEOANGIOGENESIS IN A
MAMMAL BY ADMINISTRATION OF THE
EXTRACELLULAR DOMAIN OF D1-1
POLYPEPTIDES**

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2004/0120955 A1 * 6/2004 Anderson et al. 424/146.1

(75) Inventors: **David J. Anderson**, Altadena, CA (US);
Hai U. Wang, Folsom, CA (US);
Donghun Shin, Pasadena, CA (US)

FOREIGN PATENT DOCUMENTS

(73) Assignee: **California Institute of Technology**,
Pasadena, CA (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 55 days.

This patent is subject to a terminal dis-
claimer.

EP	0561172	A1	9/1993
EP	0682113	A2	11/1995
WO	WO-00/55173	A1	9/2000
WO	WO-00/61623	A1	10/2000
WO	WO-01/57190	A2	8/2001
WO	WO-01/77289	A2	10/2001
WO	WO-02/079492	A2	10/2002

(21) Appl. No.: **11/437,755**

OTHER PUBLICATIONS

(22) Filed: **May 18, 2006**

(65) **Prior Publication Data**

US 2007/0082000 A1 Apr. 12, 2007

Delisser et al., "Platelet Endothelial Cell Adhesion Molecule
(CD31)," *Current Topics In Microbiology and Immunology* 184:37-
45(1993).

Marra et al., Accession No. AA267694 (Mar. 21, 1997).

Related U.S. Application Data

(Continued)

(63) Continuation-in-part of application No. 10/424,986,
filed on Apr. 28, 2003, now Pat. No. 7,538,088.

Primary Examiner—Bridget E Bunner

Assistant Examiner—Zachary C Howard

(60) Provisional application No. 60/375,904, filed on Apr.
26, 2002, provisional application No. 60/682,542,
filed on May 18, 2005.

(74) *Attorney, Agent, or Firm*—McCarter & English, LLP

(57) **ABSTRACT**

(51) **Int. Cl.**

A61K 38/17 (2006.01)

C07K 14/47 (2006.01)

C07K 14/515 (2006.01)

The disclosure provides, among other things, novel angiogen-
esis-related nucleic acids, polypeptides and methods of use.

(52) **U.S. Cl.** **514/12; 530/300; 530/324**

5 Claims, 17 Drawing Sheets

Human D1-1 Polypeptides

A. Full-length sequence (SEQ ID NO:10)

MGTAGAMQLCWVILGFLFRGHNSOPTMTQTSSQGGGLGLSLITTEPVSS 50
NPGYIPSEANRPSHLSSTGTGAGVPSSGRDGGTSRDTFTQVPPNSTIM 100
SLSMREDATILPSPSTSETVLTVAAGVISFIVILVVVILVGVSLRFK 150
CRKSKESDPQKPGSSGLSESCSTANGKDSITLISMKNINMNGKQSL 200
AEKVL 205

B. Extracellular portion (SEQ ID NO:11)

QPTMTQTSSQGGGLGLSLITTEPVSSNPGYIPSEANRPSHLSSTGTGAG
GVPSSGRDGGTSRDTFTQVPPNSTIMSLSMREDATILPSPSTSETVLT

C. Conserved portion (SEQ ID NO:12)

VAAFVVISFIVILVVVILVGVSLRFKCRKSKESDPQKPGSSGLSES

OTHER PUBLICATIONS

Osborn et al., "Direct Expression Cloning of Vascular Cell Adhesion Molecule1, A Cytokine-Induced Endothelial Protein That Binds to Lymphocytes," *Cell* 59:1203-1211(1989).
Genbank ref. No. XM_148854.
Genbank ref No. XP_148854.
Bork and Bairoch, 1996, Go hunting in sequence databases but watch out for the traps, *Trends in Genet.* 12(10):425-427.
Bork, 2000, Powers and Pitfalls in Sequence Analysis: The 70% Hurdle, *Genome Res.* 10:398-400.
Brenner, 1999, Errors in genome annotation, *Trends in Genet.* 15:132-133.
Doerks, 1998, Protein annotation: detective work for function prediction, *Trends in Genet.* 14(6):248-250.
Ngo et al., 1995, The Protein Folding Problem and Tertiary Structure Prediction, Chapter 14: Computational Complexity Protein Structure Prediction, and the Levinthal Paradox, pp. 492-495.
Skolnick and Fetrow, 2000, From genes to protein structure and function: novel applications of computational approaches in the genomic era, *Trends in Genet.* 18:34-39.
Smith and Zhang, 1997, The challenges of genome sequence annotation of "The devil is in the details," *Nature Biotech.* 15:1222-1223.

Staton et al., 2004, Current methods for assaying angiogenesis in vitro and in vivo, *Int. J. Exp. Path.* 85:233-248.
Wells, 1990, Additivity of Mutational Effects in Proteins, *Biochem.* 29(37):8509-8517.
Antikainen et al., "Altering protein specificity: techniques and applications," *Bioorganic & Medicinal Chemistry*, 13:2701-2716 (2005).
Armstrong, et al., "ECM2, An Endothelial Specific Filamin A Binding Protein That Mediates Chemotaxis," *Arterioscler Thromb Vasc Biol.* 28:1-7 (2008).
Auerbach, et al. "Angiogenesis Assays: A Critical Overview," *Clinical Chemistry*, 49(1):32-40 (2003).
Ferrer-Costa, et al., "Characterization of Compensated Mutations in Terms of Structural and Physico-Chemical Properties," *J. Mol. Biol.*, 365:249-256 (2007).
Ponce et al., "The Chick Chorioallantoic Membrane as an In Vivo Angiogenesis Model," *Current Protocols in Cell Biology*, Supplement 18:19.5.1-19.5.6 (2003).
Genbank ref. No. XM_148854, Date: May 17, 2002.
Genbank ref No. XP_148854, Date: May 17, 2002.

* cited by examiner




Figure 1




Figure 2

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.